Literature DB >> 8321627

Disinhibition of AVP release during noradrenaline and angiotensin II infusions in dogs by maintaining normotension with sodium nitroprusside.

M Szczypaczewska1, E Simon, C Simon-Oppermann, D A Gray.   

Abstract

Noradrenaline (NA) and angiotensin II (A II) were infused intravenously in conscious dogs without (series I) and with (series II) additional infusions of sodium nitroprusside at doses re-establishing normal levels of mean arterial pressure (MAP). In series I, NA infusion (1.6 micrograms/min per kg for 30 min) initially elevated MAP by some 25 mm Hg and lowered heart rate by some 30 beats/min. Plasma concentrations of arginine vasopressin (AVP) remained constant, while those of A II and atrial natriuretic factor were slightly, but significantly, increased. Infusion of A II (10 or 20 ng/min per kg for 30 min) induced similar rises in MAP and slight reductions of heart rate and increased plasma AVP by 70% and atrial natriuretic factor by 60%. In series II, sodium nitroprusside (1-4 micrograms/min per kg) was added for 30 min to infusions of NE (1.6 micrograms/min per kg) and A II (20 ng/min per kg) in order to maintain MAP at its control level. This resulted in an 11-fold increase in plasma AVP during NA infusion and a 19-fold increase during A II infusion. Infusing sodium nitroprusside (4 micrograms/min per kg) alone lowered MAP to clearly hypotensive levels, but the resulting rises in plasma AVP were less than, rather than equal to, those seen at normotensive MAP levels during the combined infusions of sodium nitroprusside with A II or NA, respectively. It is concluded that both NA and A II exert strong stimulatory actions on AVP release which are, however, counteracted by inhibitory influences arising from the hypertensive effects of NA and A II.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8321627     DOI: 10.1007/bf00374401

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  25 in total

Review 1.  Role of vasopressin in cardiovascular regulation.

Authors:  L Share
Journal:  Physiol Rev       Date:  1988-10       Impact factor: 37.312

2.  Independent osmoregulatory control of central and systemic angiotensin II concentrations in dogs.

Authors:  C Simon-Oppermann; D A Gray; E Simon
Journal:  Am J Physiol       Date:  1986-05

3.  Circulating catecholamines and control of plasma renin activity in conscious dogs.

Authors:  M D Johnson; D N Shier; A C Barger
Journal:  Am J Physiol       Date:  1979-03

4.  Epinephrine increases plasma immunoreactive atrial natriuretic hormone levels in humans.

Authors:  J A Sanfield; Y Shenker; R J Grekin; S G Rosen
Journal:  Am J Physiol       Date:  1987-06

5.  Central ANP administration in conscious dogs responding to dehydration and hypovolemia.

Authors:  E Szczepanska-Sadowska; C S Oppermann; E Simon; D A Gray; K Pleschka; M Szczypaczewska
Journal:  Am J Physiol       Date:  1992-05

6.  Atrial natriuretic factor--a circulating hormone stimulated by volume loading.

Authors:  R E Lang; H Thölken; D Ganten; F C Luft; H Ruskoaho; T Unger
Journal:  Nature       Date:  1985 Mar 21-27       Impact factor: 49.962

7.  The role of vasopressin in blood pressure regulation immediately following acute haemorrhage in the rat.

Authors:  J F Laycock; W Penn; D G Shirley; S J Walter
Journal:  J Physiol       Date:  1979-11       Impact factor: 5.182

8.  Central adrenergic control of vasopressin release.

Authors:  D P Brooks; L Share; J T Crofton
Journal:  Neuroendocrinology       Date:  1986       Impact factor: 4.914

9.  Repeated hypotension induced by nitroprusside and haemorrhage in sheep: effects on vasopressin release and recovery of arterial blood pressure.

Authors:  H Jonasson; H Hjelmqvist; M Rundgren
Journal:  Acta Physiol Scand       Date:  1989-11

10.  Central atrial natriuretic factor reduces vasopressin secretion in the rat.

Authors:  K Iitake; L Share; J T Crofton; D P Brooks; Y Ouchi; E H Blaine
Journal:  Endocrinology       Date:  1986-07       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.